Date: 2013-11-12
Type of information: Collaboration agreement
Compound: novel targets in scleroderma
Company: Biofocus, a Galapagos Company (UK - Belgium) BiogenIdec (USA -MA)
Therapeutic area: Autoimmune diseases
Type agreement:
Action mechanism:
Disease: scleroderma
Details: * On November 12 2013, Galapagos has announced that its subsidiary BioFocus signed a 3-year collaboration agreement with Biogen Idec focused on the identification and validation of novel targets in scleroderma. BioFocus will use its SilenceSelect® platform and unique human skin models to deliver new assays and identify validated, novel, disease-modifying targets in scleroderma to Biogen Idec.
Financial terms: Under the terms of the agreement, BioFocus will receive an upfront payment, FTE funding, and will be eligible to receive success payments for target discovery milestones to be delivered by BioFocus and development milestones achieved by Biogen Idec. The total value of this collaboration to BioFocus could reach $31 million.
Latest news:
